Kornimate/medical-research-clean huggingface dataset:
ketogenic diet improves thrombocytopenia in cancer patients

Conditions: Ketogenic Diet

Summary: the main purpose of this study is to evaluate whether dietary intervention through ketogenic diet can prevent or improve chemotherapy related thrombocytopenia in cancer patients.

in the study, 80 patients with malignant solid tumors undergoing chemotherapy were randomly assigned to the normal diet group, the strict ketogenic diet group, the circulating ketogenic diet group, and the autonomous ketogenic group. during the chemotherapy period, the corresponding dietary intervention was carried out, and the clinical data of patients before and after treatment were collected, including blood routine, blood ketone concentration, weight, blood sugar, blood lipids, adverse events, and changes in platelets before and after chemotherapy, statistical analysis of data such as the change degree of platelets and the incidence of adverse events in each diet group before and after treatment was carried out to evaluate the impact of ketogenic diet on clinical indicators and adverse reactions of chemotherapy in cancer patients.

Eligibility criteria:
inclusion criteria: * between the ages of 18 and 90, regardless of gender * ecog score ≤ 2 points * received or expected to receive radiotherapy and chemotherapy during tumor activity * body mass index 19-29 * conscious and autonomous eaters exclusion criteria: * patients with basic diseases of diabetes * complications such as severe liver and kidney dysfunction or digestive tract obstruction, inability to eat * those who have a preference for food and have strict requirements for dietary taste * disagree to sign informed consent * those whose physical conditions are determined by the doctor to be impermissible
effect of sacral erector spinae plane block on hemorrhoid and pilonidal sinus surgery

Conditions: Pain, Acute Post-Operative; Pilonidal Sinus; Hemorrhoids; Anesthesia

Summary: introduction: this study investigated the efficacy of sacral erector spinae plane block (espb) for managing postoperative pain and reducing opioid consumption in patients undergoing hemorrhoid and pilonidal sinus (ps) surgery.

introduction: this study investigated the efficacy of sacral erector spinae plane block (espb) for managing postoperative pain and reducing opioid consumption in patients undergoing hemorrhoid and pilonidal sinus (ps) surgery.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i-ii patients undergoing hemorrhoid and pilonidal sinus surgery exclusion criteria: * patients with coagulopathies, pregnant women, patients with significant cardiovascular, hepatic, or renal disease, patients who declined spinal anesthesia or were contraindicated for it, and patients who had previously undergone the same surgery

Keywords: sacral espb postoperative pain hemorrhoidectomy pilonidal sinus surgery analgesia
migrainemanager: an individualized self-management tool for adolescents with migraine

Conditions: Migraine Disorders

Summary: the purpose of the study is to develop, evaluate, and optimize "migrainemanager", the first web-based comprehensive self-management tool for adolescents with migraine, their parents, and clinicians.


Eligibility criteria:
inclusion criteria: * patient is diagnosed with migraines using current international classification of headache disorders criteria (ichd-3 beta) for migraine with or without aura * patient has headache frequency of 8+ per month * access to the internet whether public (e.g., library) or private (e.g., home, personal) * english fluency for patient, caregiver, and clinician exclusion criteria: * diagnosis of pervasive developmental disorder in patient or caregiver as determined by medical chart review * diagnosis of serious mental illness (e.g., schizophrenia) in patient or caregiver as determined by medical chart review

Keywords: migraine
anti-carbamylated protein antibodies in psoriatic arthritis

Conditions: Psoriasis; Arthritis, Psoriatic

Summary: anti-carbamylated protein (anti-carp) antibodies are present in approximately one-fourth of the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein antibody and who may therefore have psoriatic arthritis. the investigators hypothesized that detection of anti-carp antibodies in serum may be useful for diagnosis of psoriatic arthritis.


Eligibility criteria:
inclusion criteria: * "controls" : patients with a psoriasis confirmed by a dermatologist and with absence of psoriatic arthritis confirmed by a rheumatologist. * "cases" : patients with psoriatic arthritis fulfilling the classification criteria for psoriatic arthritis (caspar), with a diagnosis confirmed by a rheumatologist and associated with personal or familial psoriasis. exclusion criteria: * "controls": presence of any chronic rheumatic inflammatory disease such as psoriatic arthritis.
expiratory flow accelerator (efa) vs efa + high flow in chronic copd and bronchiectasis

Conditions: Copd; Bronchiectasis Adult

Summary: the aim of the study is to compare the efficacy of using efa technology versus the combination of efa + high flow in hypersecretory patients copd and bronchiectasis

after being informed about the study and potential risks, all patients giving written informed consent will undergo a 13-weeks trial period: 6 weeks of one technology (efa / efa+ high flow), 1- wash out week and 6- weeks of the other technology in a cross over randomized trial.

Eligibility criteria:
inclusion criteria: * copd diagnosed by spirometry * bronchiectasis diagnosed by ct * 2 exacerbation/year exclusion criteria: * cystic fibrosis * osas * non invasive ventilation * ineffective cough * exacerbation in progress * hemodynamic instability * severe heart failure

Keywords: efa high flow bronchiectasis copd hypersecretion
the effect of heat on blood and oxygen flow readings part 2

Conditions: Healthy; Peripheral Vascular Disease; Vasoconstriction

Summary: this is the second part of a research study in order to determine if using a specialized pulse oximetry probe with external heat pack will help obtain oxygen saturation (sao2) and heart rate (hr) during monitoring for patients with peripheral vascular disease (pvd), vasoconstriction, and hypothermic extremities. the inability to obtain accurate sao2 and pulse readings can lead to misdiagnosis, incorrect treatment, or procedures to be canceled. sao2 and pulse readings are important to maintain patient stability during diagnostic testing, surgical procedures and monitoring while in critical care areas. changes in sao2 and pulse are important to monitor in order to be able to compensate for any decrease in patient oxygen saturations during hemodynamic monitoring. the primary aim of this study is to determine if using a specialized pulse oximetry probe with external heat pack will improve oxygenation readings in order to obtain sao2 and pulse readings in patients with pvd, vasoconstriction, and hypothermic extremities as compared to readings obtained from an arterial blood gas. the hypothesis is using a specialized pulse oximetry probe with external heat pack will help obtain more accurate pulse oximetry readings consistent with values obtained with an arterial blood gas.

150 patients will be approached in order to ensure 110 patients will be enrolled in this study total. 30 patients will have peripheral vascular disease (pvd), vasoconstriction, or hypothermic extremities and 80 patients with no blood flow issues will be enrolled. the patients will serve as their own controls. each patient will have a specialized pulse oximetry probe with external heat pack added to their extremity while measuring pulse oximetry. these sao2 readings will be compared to sao2 readings obtained from an arterial blood gas obtained during the course of the study.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years 2. able to give informed consent 3. patients must be able to read and understand english. 4. patients scheduled to enter the va pittsburgh healthcare system catheterization lab arm 2 of the study: 1. the pi will determine if patients have poor circulation due to obstruction of the large arteries in their arms and legs (peripheral vascular disease (pvd), narrowing of their blood vessels (vasoconstriction), or extremities (arms, legs, etc) that are at least 3 degrees fahrenheit below their normal body temperature. if patients do have any of the following they will be considered for arm 2. if they do not they will be considered for arm 1. exclusion criteria: in addition to the exclusions mentioned above, patients with the following conditions will be excluded from the trial: 1. inability or unwillingness to sign informed consent with free will and sound mind, as determined by a score of \<11 on the evaluation to sign consent form.

Keywords: pulse heat blood circulation
comparison between everolimus-eluting stent (ees) and sirolimus-eluting stent (ses) in the bifurcation lesion

Conditions: Ischemic Heart Disease

Summary: in study-1, the purpose of this study is to compare the long-term outcome of provisional stenting between ees and ses deployment. in study-2, it is to prove the following hypothesis " asymmetrical expansion in the bifurcation lesion leads to frequent inhomogeneous intimal growth on the strut and thrombus attachment."

kissing balloon inflation brings asymmetrical expansion which may lead to a risk of disturbance of endothelialization. we will investigate the following issues. 1. impact of asymmetric expansion induced by kissing balloon technique on mid and long term results 2. difference between ses and ees 3. impact of abnormal oct findings on long-term clinical outcome (3yr)

Eligibility criteria:
inclusion criteria: 1. coronary bifurcation lesion which stenotic lesion exists in the mv and / or in the side branch (sb). 2. the lesion is appropriate for the provisional mv stenting. 3. the reference diameter is more than 2.5mm in the mv and more than 2.0mm in the sb. exclusion criteria: 1. left main coronary bifurcation 2. acute myocardial infarction and unstable angina which culprit vessel contains obvious thrombus 3. left ventricular ejection fraction \< 30% 4. shock state 5. inappropriate candidate for the dual antiplatelet therapy, administration of contrast medium and radiation

Keywords: bifurcation lesion, drug-eluting stent, symmetric expansion
prospective study of efficacy of intra-muscular vitamin d3 in tropical calcific pancreatitis

Conditions: Pancreatitis, Chronic

Summary: the purpose of this study is to determine the efficacy of 2 different doses of intramuscular (im) vitamin d3 as compared to an oral replacement dose in normalizing vitamin d levels in the blood of patients with tropical calcific pancreatitis.

tropical calcific pancreatitis (tcp) is a form of chronic pancreatitis unique to developing countries. patients with tcp often have malabsorption leading to nutritional deficiencies. we have noted that vitamin d deficiency is common in patients with tcp. the ideal regimen for supplementing vitamin d3 in chronic pancreatitis remains unclear and there are no previous studies available. high dose oral vitamin d2 has been shown to be ineffective in normalizing vitamin d levels in patients with pancreatic insufficiency due to cystic fibrosis. intramuscular (im) vitamin d3 supplementation in chronic pancreatitis has certain advantages. firstly, decreased and inconsistent absorption from the intestine is avoided. secondly, im vitamin d3 has a long duration of action (6-12 months). the safety of high-dose im vitamin d3 has been proven in previous studies in healthy individuals. finally, the injection form is considerably less expensive as compared to oral vitamin d3. the aim of the current prospective double blind study is to compare 2 regimens of high dose im vitamin d3 replenishment with oral vitamin d3 in standard recommended doses in normalizing serum vitamin d3 levels in patients with tcp.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of tropical calcific pancreatitis established by history of abdominal pain or diabetes and evidence on ultrasound or ct scan of pancreatic ductal dilatation and intra-ductal stones exclusion criteria: * history of alcohol intake or any secondary cause for chronic pancreatitis (hypercalcemia, hypertriglyceridemia, biliary tract stones) * history of hepatic or renal dysfunction or of current intake of drugs such as steroids, anticonvulsant drugs

Keywords: tropical calcific pancreatitis tropical chronic pancreatitis chronic pancreatitis vitamin d vitamin d deficiency cholecalciferol intramuscular vitamin d3
study of dronabinol treatment for depression and/or anxiety in older patients

Conditions: Depression, Anxiety

Summary: this is an observational study evaluating the safety and efficacy of dronabinol for the treatment of anxiety and/or depression in older adults. participants who are prescribed dronabinol as part of a voluntary inpatient stay in mclean's division of geriatric psychiatry will be interviewed about their mood and cognition on a weekly basis while on dronabinol.

recently there has been renewed interest in potential alternative medical applications of cannabis/thc and medical marijuana is now legalized in 23 states and the district of columbia. acute effects of thc can include subjective feelings of euphoria, relaxation, and sedation, and clinicians noted that thc is well tolerated for its approved indications. given these subjective effects and relatively benign safety profile, some physicians have used dronabinol (synthetic thc) "off-label" to treat depression and/or anxiety. the investigators are doing this research to better understand how effective dronabinol treatment is when prescribed for depression and/or anxiety in older patients. the investigators also want to find out if dronabinol is safe to take without causing too many side effects. dronabinol is is approved by the u.s. food and drug administration (fda) to treat loss of appetite in chemotherapy patients, but dronabinol is not approved by the fda to treat depression and/or anxiety. through research questionnaires on mood and cognition, the investigators can gather information that will help demonstrate how effective dronabinol treatment is at treating depression and/or anxiety.

Eligibility criteria:
inclusion criteria: 1. 50-89 years old (inclusive) 2. inpatient on the older adult unit in south belknap 1 at mclean hospital 3. initiating dronabinol therapy for the treatment of any diagnostic and statistical manual (dsm) 5 major depression or anxiety disorder diagnosis 4. ability to provide informed consent 5. must be fluent in english exclusion criteria: 1. delirium as determined by the confusion assessment method (cam) 2. serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, which might confound assessment of safety outcomes 3. seizure disorder 4. diagnosis of bipolar depression, major depression with psychotic features, schizophrenia, schizoaffective disorder, dementia 5. use of dronabinol or marijuana in the last year 6. prescription of lithium or anticonvulsant medications (except gabapentin) 7. patient currently admitted involuntarily to mclean hospital

Keywords: late life thc depression anxiety dronabinol
injection site tolerability, safety, pharmacokinetics and pharmacodynamics study after a single dose subcutaneous treatment of alirocumab sar236553 (regn727)

Conditions: Hypercholesterolemia

Summary: primary objective: injection site tolerability secondary objectives: * to assess the safety profile of alirocumab sar236553 (regn727) * to assess the pharmacokinetic-pharmacodynamic relationship of alirocumab sar236553 (regn727)

the total duration of study for each subject is up to 15 weeks including a screening period up to 3 weeks.

Eligibility criteria:
inclusion criteria: * serum troponin i level should not exceed the upper laboratory limit of normal. * male or female subject, between 18 and 65 years inclusive. * body weight between 50.0 and 95.0 kg inclusive if male, between 40.0 kg and 85.0 kg inclusive if female, body mass index (bmi) between 18.0 and 30.0 kg/m² inclusive. * certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * normal vital signs after 10 minutes resting in supine position. * normal standard 12-lead ecg after 10 minutes resting in supine position. * laboratory parameters within the normal range, unless the investigator considers an abnormality to be clinically irrelevant for healthy subjects * if female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal. * serum ldl-c levels\>100 mg/dl at screening visit. exclusion criteria: * subjects indicated for the use of statins according to criteria in national cholesterol education program adult treatment panel iii guidelines, as updated in 2004 (see appendix c). * initiation of a new diet or major change to a previous diet within 4 weeks prior to screening (day -21 to -2). subjects must be willing to maintain a consistent diet for the duration of the study. * use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening (day -21 to -2), including but not limited to statins, ezetimibe, fibrates, niacin, or omega-3 fatty acids, bile acid resins. * fasting serum triglycerides \>200 mg/dl measured after an 8 to 12 hour fast. * history of a hypersensitivity reaction to doxycycline or similar compound. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
poc for the treatment of subjects with moderate as using valvosoft® non-invasive ultrasound therapy

Conditions: Moderate Aortic Valve Stenosis

Summary: this study is a proof of concept looking at the safety of treating subjects with moderate aortic stenosis using a non-invasive ultrasound therapy.

valvosoft, ultrasound guided non-invasive ultrasound therapy (niut) medical device, delivers focused and controlled, short ultrasound pulses (\<20μsec), directed trans-thoracically at a high acoustic intensity (measured in watts per square centimeter (w/cm2), to produce non-thermal mechanical tissue softening of the targeted calcified aortic valve. echocardiographic live imaging enables to follow valve movements in real-time and thus target the therapeutic ultrasound on the calcified valve with great precision. this is first in human or proof of concept study.

Eligibility criteria:
inclusion criteria: 1. aortic valve area (ava) ≥1.0 cm2 ≤ 1.5 cm2 and either mean aortic pressure gradient (mpg) of \>25 - \< 40 mmhg or maximum velocity (vmax) ≥3 ≤4 m/sec in normal flow conditions; or 2. normal-flow, low-gradient aortic stenosis (as) with preserved ejection fraction (mean aortic pressure gradient (mpg) \ 35 ml/m2); 3. age ≥18 years; exclusion criteria: 1. mpg ≥40 mmhg; or 2. severe aortic valve stenosis or other severe valve diseases; or 3. subject with severe aortic regurgitation; or 4. subjects with implanted mechanical or bioprosthetic valve in aortic position, or mechanical valve in any other positions; or 5. heart failure with a nyha 3 or 4; or 6. cardiogenic shock or other hemodynamic instability; or 7. lvef ≤50%; or 8. history of heart transplant; or 9. subject with a significant kidney disease (egfr ≤30 ml/min/1.73 m2) or subject is on dialysis; or 10. subject with uncontrolled hypertension defined as systolic blood pressure (bp) ≥160 mmhg and/or a diastolic bp ≥100 mmhg (mean of 3 measurements for both assessments); or 11. cardiac imaging evidence of vegetation; or 12. current endocarditis; or 13 subject has a documented history of cardiac amyloidosis; or 14. acute myocardial infarction (mi) ≤1 month prior to enrolment; or 15. stroke or transient ischemic attack (tia) ≤1 month prior to enrollment; or 16. balloon aortic valvuloplasty (bav) ≤3 months prior to enrollment; or 17. leukopenia (wbc \<4000 cell/μl), anemia (hgb \< 8 g/dl), thrombocytopenia (platelet count \<50.000 cell/μl), or history of coagulopathy or hypercoagulable state.

Keywords: aortic stenosis moderate aortic valve balloon valvuloplasty tavr savr ultrasound fus pcut niut
efecab: improving pig management to prevent epilepsy in burkina faso

Conditions: Cysticercosis

Summary: this is a pre-post randomized community-based controlled trial aimed at estimating the effectiveness of an educational package developed using precede proceed to reduce the cumulative incidence of taenia solium cysticercosis in three provinces of burkina faso. the study design included an 18-months baseline study to measure baseline cumulative incidence of cysticercosis followed by an 18-month post randomization study to measure the effectiveness of the intervention. sixty villages of three provinces of burkina faso were included. the primary outcome was the change in the baseline to post randomization cumulative incidence in the intervention group compared to the control group.


Eligibility criteria:
the unit of randomization and analysis of this study is the village. therefore, the eligibility criteria were determined at the village level. inclusion criteria: * population of at least 1000 at the 2006 census * present on the map of the "institut géographique du burkina 2000" * separated from another village by at least 5 kilometers. exclusion criteria: * village located on a national or provincial road * village located within 20 km of koudougou or ouagadougou * regional or provincial capital * absence of pigs in the village at the individual level, the following eligibility criteria were used: inclusion criteria: * aged 5 years old or more * has lived in the village for at least 12 months * not planning to move in the next three years exclusion criteria: * presence of confirmed epilepsy or progressively worsening severe chronic headaches at baseline.

Keywords: burkina faso community-based randomized controlled trial cysticercosis implementation research effectiveness